KEGG   DRUG: D09314Help
Entry
D09314                      Drug                                   

Name
Ofatumumab (genetical recombination) (JAN);
Ofatumumab (USAN/INN);
Arzerra (TN)
Product
Formula
C6480H10022N1742O2020S44
Exact mass
145970.276
Mol weight
146060.2301
Activity
Treatment of chronic lymphocytic leukemia [DS:H00005]
Remark
Therapeutic category: 
ATC code: 
Comment
hunan IgG1 anti-CD20 monoclonal antibody
Target
CD20 [HSA:931] [KO:K06466]
  Pathway
hsa04640  Hematopoietic cell lineage  
 
Interaction
Genomic biomarker: CD20 [HSA:931]
Drug interaction
Structure map
Antirheumatics - DMARDs and biological agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC10 Ofatumumab
      D09314  Ofatumumab (genetical recombination) (JAN); Ofatumumab (USAN/INN)
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibodies
   Ofatumumab
    D09314  Ofatumumab (genetical recombination) (JAN); Ofatumumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D09314  Ofatumumab (genetical recombination) (JAN); Ofatumumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Others
  Cellular antigens
   CD20
    Ofatumumab
     D09314  Ofatumumab (genetical recombination) (JAN); Ofatumumab (USAN/INN)
Antineoplastics [BR:br08308]
 Molecularly targeted agents
  Monoclonal antibody
   Ofatumumab
    D09314  Ofatumumab (genetical recombination) (JAN); Ofatumumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
679818-59-8
PubChem: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system